Systematic validation of novel breast cancer progression-associated biomarkers via high-throughput antibody generation and application of tissue microarray technology: An initial report No significant ...
Symptomatic brain metastases from renal cell carcinoma during treatment with sunitinib or sorafenib. Background: Germline mutations in the VHL gene cause VHL syndrome. Functional loss of the VHL gene ...
An expert explains the basics of von Hippel-Lindau—related kidney cancer, and how a new drug for the disease is shaping the way patients are treated. Patients with von Hippel-Lindau (VHL) disease are ...
WELIREG is the first and only systemic therapy approved in China for adult patients with certain VHL disease-associated tumors Decision marks first approval for WELIREG in China and 17th approval of ...
Von Hippel-Lindau disease (VHL), also called VHL syndrome, is a rare genetic disorder that causes tumors and cysts to form throughout your body. VHL disease can be found all over the world across all ...
RCC contributes to approximately 4% of adult malignancies. To date, four major inherited RCC syndromes have been identified. This PDQ summary provides a reference on the genetics of RCC for clinicians ...
WELIREG Approved for Adult Patients With VHL Disease Who Require Therapy for Associated Renal Cell Carcinoma, Central Nervous System Hemangioblastomas, or Pancreatic Neuroendocrine Tumors, Not ...
Decision marks first approval for WELIREG in China and 17th approval of WELIREG for these patients globally In August 2021, WELIREG was approved in the U.S. for the treatment of adult patients with ...
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved WELIREG, an oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback